OA38 Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement

Abstract

Background: Patients (pts) with psoriatic arthritis (PsA) and axial involvment exhibit greater disease activity and quality of life impairments compared with those without axial involvment. Objective(s): To characterize PsA pts with and without axial involvement and compare efficacy of UPA vs placebo (PBO) in PsA pts with axial involvement. Method(s): In SELECT-PsA 1 (NCT03104400; N=1705, non-biologic DMARD IR) and SELECT-PsA 2 (NCT03104374; N=642, biologic DMARD IR), pts with active PsA (>=3 swollen and >=3 tender joints), active or historical psoriasis, and on